T2 Biosystems, Inc.
TTOODelisted Jul 10, 2025- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001492674
T2 Biosystems, Inc. was delisted on Jul 10, 2025; its insiders filed their last Form 4 on Jan 2, 2025; 1 institution reported holding it in 13F filings for Q2 2025, worth $0 in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 1
- Q2 2025, −1 vs. previous quarter
- 13F value
- $0
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding TTOO, Q2 2025
No superinvestor reported holding TTOO at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by T2 Biosystems, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2024 (view filing) | Sep 13 | 4 days | Elsbree David BDirector | SSale | −55 | $2.42 | −$133.1 | −70.5%23 after | |
| Nov 28, 2023 (view filing) | Feb 20 | 281 days | Giffin Brett A.Chief Commercial Officer | SSale | −537 | $0.65 | −$349.05 | −15.0%3.05K after | Amended |
| Sep 29, 2023 (view filing)4:30 PM ET | Sep 27-28 | 2 days | CRG Partners III L.P. and 4 others10% Owner | SSale | −13.1M | $0.173 | −$2.27M | −100.0%0 after | 8 lots |
| Sep 28, 2023 (view filing)4:30 PM ET | Sep 26 | 2 days | CRG Partners III L.P. and 4 others10% Owner | SSale | −5.39M | $0.2007 | −$1.08M | −60.2%3.56M after | 4 lots |
| Sep 27, 2023 (view filing)5:53 PM ET | Sep 25 | 2 days | CRG Partners III L.P. and 4 others10% Owner | SSale | −250.0K | $0.25 | −$62.5K | −4.7%5.02M after | 4 lots |
| Sep 26, 2023 (view filing)5:15 PM ET | Sep 22 | 4 days | CRG Partners III L.P. and 4 others10% Owner | SSale | −5.08M | $0.2588 | −$1.31M | −50.0%5.09M after | 4 lots |
| Sep 25, 2023 (view filing)8:30 PM ET | Sep 21 | 4 days | CRG Partners III L.P. and 4 others10% Owner | SSale | −6.34M | $0.3005 | −$1.90M | −49.5%6.47M after | 4 lots |
| Sep 22, 2023 (view filing)4:15 PM ET | Sep 20 | 2 days | CRG Partners III L.P. and 4 others10% Owner | SSale | −7.75M | $0.3106 | −$2.41M | −48.7%8.18M after | 4 lots |
| Sep 21, 2023 (view filing)4:30 PM ET | Sep 19 | 2 days | CRG Partners III L.P. and 4 others10% Owner | SSale | −10.4M | $0.366 | −$3.81M | −50.3%10.3M after | 4 lots |
| Apr 6, 2023 (view filing)1:08 PM ET | Mar 28 | 9 daysLate | Gibbs Michael TerrenceGeneral Counsel | SSale | −239 | $0.481 | −$114.96 | −3.5%6.61K after |
Top 10 13F holders, Q2 2025
The largest institutional positions in T2 Biosystems, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Union Bancaire Privee, UBP SA | 1 | $0 | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of TTOO
Holders whose latest Schedule 13D or 13G filing reports 5% or more of T2 Biosystems, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| JSAF Holdings, LLC | 13G/A | 5.30%1.50M shares | – | Feb 13, 20251 filing | Feb 13, 2025 | SEC |
| Safier Jacob | 13G/A | 5.30%1.50M shares | – | Feb 13, 20251 filing | Feb 13, 2025 | SEC |